COMPENSATION MAY BE AVAILABLE FOR BREAST CANCER SURVIVORS SUFFERING FROM PERMANENT BALDNESS (ALOPECIA); DECEPTIVE MARKETING OF TAXOTERE CHEMOTHERAPY DRUG

The Smith Law Firm, and other law firms in and outside of St. Louis, Missouri, have launched an investigation into the deceptive marketing of chemotherapy drug Taxotere by Sanofi Aventis.  We believe that Sanofi Aventis hid data suggesting that Taxotere caused permanent baldness in order to increase market share over equally effective competing chemotherapy drugs. 

Sanofi created Taxotere as patented chemotherapy drug for the treatment of breast cancer in women.  In applying for the patent, Sanofi claimed that Taxotere was a superior type of chemotherapy drug, exceeding the effectiveness of other drugs on the market.  In reality, we believe that Taxotere was no more effective than any other drug on the market for treating women with Stages 1 and 2 breast cancer.  Worse yet, in 6.3% of its users Taxotere also caused permanent and irreversible baldness (alopecia).

For more information click here.

When given a choice between two chemotherapy drugs that are equally effective at treating breast cancer, and equal in all other respects, almost all women would choose the one that does not carry a risk of permanent baldness.  If you or a family member suffered from permanent alopecia we would love to speak with you.  Please call us at (314) 725-4400 or send us an email.